Pfizer (PFE) reported Q4 FY 2020 earnings of $0.42 per share (versus $0.55 per share in Q4 FY 2019), missing analysts’ consensus estimate of $0.46 per share.
The company’s quarterly revenues amounted to $11.684 bln (+11.8% y/y), beating analysts’ consensus estimate of $11.322 bln.
The company also issued upside guidance for FY 2021, projecting EPS of $3.10-3.20 versus analysts’ consensus estimate of $2.97 and its prior guidance of $3.00-3.10 and revenues of $59.4-61.4 bln versus analysts’ consensus estimate of $48.51 bln.
PFE rose to $36.00 (+0.56%) in pre-market trading.